Catalogue Search | MBRL
Are you sure you want to remove the book from the shelf?
{{itemTitle}}
497
result(s) for
"License agreements -- United States"
Sort by:
Intellectual Property
A new edition of the trusted book on intellectual property
Intellectual Property simplifies the process of attaching a dollar amount to intellectual property and intangible assets, be it for licensing, mergers and acquisitions, loan collateral, investment purposes, and determining infringement damages.
Written by Russell L. Parr, an expert in the valuation/intellectual property field, this book comprehensively addresses IP Valuation, the Exploitation Strategies of Licensing and Joint Ventures, and determination of Infringement Damages. The author explains commonly used strategies for determining the value of intellectual property, as well as methods used to set royalty rates based on investment rates of returns.
This book examines the business economics of strategies involving intellectual property licensing and joint ventures, provides analytical models that can be used to determine reasonable royalty rates for licensing and for determining fair equity splits in joint venture arrangements.
Key concepts in this book are brought to life by presenting real-world examples of exploitation strategies being used by major corporations.
* Provides practical tools for and examines the business economics for determining the value intellectual property in licensing and joint venture decisions
* Presents analytical models for determining reasonable royalty rates for licensing and for determining fair equity splits in joint venture arrangements
* Provides a detailed discussion about determining intellectual property infringement damages focusing on lost profits and reasonable royalties.
eBook
Franchising & licensing : two powerful ways to grow your business in any economy
Growing your business doesn't have to be messy or complicated. This indispensable reference provides legal insider insight into how to leverage the intellectual capital of your company to generate new revenue.
eBook
Licensing digital content : a practical guide for librarians
In its new edition, this resource remains a must-have for all information professionals who deal with licenses for electronic resources.
eBook
Broadcasting Hollywood
Broadcasting Hollywood: The Struggle Over Feature Films on
Early Television uses extensive archival research into the
files of studios, networks, advertising agencies, unions and
guilds, theatre associations, the FCC, and key legal cases to
analyze the tensions and synergies between the film and television
industries in the early years of television. This analysis of the
case study of the struggle over Hollywood's feature films appearing
on television in the 1940s and 1950s illustrates that the notion of
an industry misunderstands the complex array of
stakeholders who work in and profit from a media sector, and models
a variegated examination of the history of media industries.
Ultimately, it draws a parallel to the contemporary period and the
introduction of digital media to highlight the fact that history
repeats itself and can therefore play a key role in helping media
industry scholars and practitioners to understand and navigate
contemporary industrial phenomena.
eBook
Licensing digital content
\"Covering the basics of digital licensing for librarians, the new third edition provides a freshened look at all the key issues as well as updated sample agreement clauses. [This book will give] library professionals and students the understanding and the tools needed to negotiate and organize license agreements.\"
eBook
Franchising & licensing : two powerful ways to grow your business in any economy
Fully revised, completely updated, and still the definitive guide to these great business strategies.
eBook
Intellectual property : valuation, exploitation, and infringement damages
This book is designed to simplify the process of attaching a dollar amount to intangible assets, be it for licensing, mergers and acquisitions, loan collateral, or investment purposes. It provides practical tools for evaluating the investment aspects of licensing and joint venture decisions, and discusses the legal, tax, and accounting practices and procedures related to such arrangements; examines the business economics of strategies involving intellectual property licensing and joint ventures; and provides analytical models that can be used to determine reasonable royalty rates for licensing and for determining fair equity splits in joint venture arrangements.
eBook
A roadmap for affordable genetic medicines
Twenty genetic therapies have been approved by the US Food and Drug Administration to date, a number that now includes the first CRISPR genome-editing therapy for sickle cell disease—CASGEVY (exagamglogene autotemcel, Vertex Pharmaceuticals). This extraordinary milestone is widely celebrated owing to the promise for future genome-editing treatments of previously intractable genetic disorders and cancers. At the same time, such genetic therapies are the most expensive drugs on the market, with list prices exceeding US$4 million per patient. Although all approved cell and gene therapies trace their origins to academic or government research institutions, reliance on for-profit pharmaceutical companies for subsequent development and commercialization results in prices that prioritize recouping investments, paying for candidate product failures and meeting investor and shareholder expectations. To increase affordability and access, sustainable discovery-to-market alternatives are needed that address system-wide deficiencies. Here we present recommendations of a multidisciplinary task force assembled to chart such a path. We describe a pricing structure that, once implemented, could reduce per-patient cost tenfold and propose a business model that distributes responsibilities while leveraging diverse funding sources. We also outline how academic licensing provisions, manufacturing innovation and supportive regulations can reduce cost and enable broader patient treatment.
Implementation of new pricing and business structures and improved licensing and manufacturing processes could reduce the per-patient cost of gene therapy tenfold.
Journal Article